Indefinite Delivery Contract SPE2DX15D9385

The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, with a ceiling value of $4,999,999.00 through December 2025. The contract enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products and medical supplies, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide under the TRICARE West program.

DMS Pharmaceutical Group also holds a larger $499,999,999 IDC with DLA under the SPE2DB program, which provides the agency additional flexibility to procure a diverse portfolio of pharmaceutical items to support the medical supply requirements of Department of Defense healthcare sites globally. The contract does not have any set-aside designations, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal awards across multiple product categories and medical domains.